Monitoring multiple myeloma patients treated with daratumumab: Teasing out monoclonal antibody interference

Clinical Chemistry and Laboratory Medicine

Volumn 54, Issue 6, 2016, Pages 1095-1104

  McCudden, Christopher ^a   Axel, Amy E ^b   Slaets, Dominique ^c   Dejoie, Thomas ^d   Clemens, Pamela L ^b   Frans, Sandy ^b   Bald, Jaime ^b   Plesner, Torben ^e   Jacobs, Joannes F M ^f   Van De Donk, Niels W C J ^g   Moreau, Philippe ^h   Schecter, Jordan M ⁱ   Ahmadi, Tahamtan ^b   Sasser, A Kate ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c BARC   (Belgium)

^d Nantes Hospital   (France)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h NANTES UNIVERSITY HOSPITAL   (France)

ⁱ JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

complete response; daratumumab; immunofixation electrophoresis; monoclonal antibody; multiple myeloma

Indexed keywords

DARATUMUMAB; DRUG ANTIBODY; M PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; MONOCLONAL ANTIBODY; PARAPROTEIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DARATUMUMAB SPECIFIC IMMUNOFIXATION ELECTROPHORESIS REFLEX ASSAY; ELECTROPHORESIS; HUMAN; IMMUNOASSAY; IMMUNOFIXATION ELECTROPHORESIS; LIMIT OF DETECTION; MULTIPLE MYELOMA; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SERUM PROTEIN ELECTROPHORESIS; ANIMAL; BLOOD; CROSS REACTION; DIAGNOSTIC ERROR; IMMUNOELECTROPHORESIS; IMMUNOLOGY; MOUSE; PREVENTION AND CONTROL;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD PROTEIN ELECTROPHORESIS; CROSS REACTIONS; DIAGNOSTIC ERRORS; HUMANS; IMMUNOELECTROPHORESIS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA-CHAINS; LIMIT OF DETECTION; MICE; MULTIPLE MYELOMA; MYELOMA PROTEINS; REPRODUCIBILITY OF RESULTS;

EID: 84969835048     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2015-1031     Document Type: Article

References (22)

1. Axel AE, McCudden CR, Xie H, Hall BM, Sasser AK. Development of clinical assay to mitigate daratumumab, an IgG1k monoclonal antibody, interference with serum immunofixation (IFE) and clinical assessment of M-protein response in multiple myeloma. Cancer Res 2014;74(Suppl. 19). Abstract 2563.
2. Zent CS, Wilson CS, Tricot G, Jagannath S, Siegel D, Desikan KR, et al. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood 1998;91:3518-23.
3. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73.
4. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117:4691-5.
5. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3-9.
6. Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015;373:1207-19.
7. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015;373:621-31.
8. Lonial S, Weiss B, Usmani S, Singhal S, Chari A, Bahlis N, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial. Lancet. 2016 Jan 6. pii: S0140-6736(15)01120-4. doi: 10.1016/S0140-6736(15)01120-4. [Epub ahead of print].
9. Genzen JR, Kawaguchi KR, Furman RR. Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis. Br J Haematol 2011;155:123-5.
10. McCudden CR, Voorhees PM, Hainsworth SA, Whinna HC, Chapman JF, Hammett-Stabler CA, et al. Interference of monoclonal antibody therapies with serum protein electrophoresis tests. Clin Chem 2010;56:1897-9.
11. Dimopoulos M, Lonial S, Casado LF, Golightly M, Doyen C, Shelat S, et al. Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma (RRMM). Poster presented at: 15th International Myeloma Workshop; September 23-26, 2015; Rome, Italy.
12. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011;186:1840-8.
13. Jansen JH, Boross P, Overdijk MB, Lammerts van Bueren JJ, Parren PW, Leusen HH. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptormediated crosslinking. Blood 2012;120. Abstract 2974.
14. Lammerts van Bueren J, Jakobs D, Kaldenhoven N, Roza M, Hiddingh S, Meesters J, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Abstract presented at: 56th ASH Annual Meeting and Exposition; December 6-9, 2014; San Francisco, CA. Abstract 3474.
15. Overdijk MB, Verploegen S, Bogels M, van Egmond M, Lammerts van Bueren JJ, Mutis T, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 2015;7:311-21.
16. Krejcik J, Casneuf T, Nijhof I, Verbist B, Bald J, Plesner T, et al. Immunomodulatory effects and adaptive immune response to daratumumab in multiple myeloma. Blood 2015;126. Abstract 3037.
17. McKeage K. Daratumumab: first global approval. Drugs 2016;76:275-81.
18. McCudden C, Axel A, Slaets D, Frans S, Bald J, Schecter JM, et al. Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody. J Clin Oncol 2015;33. Abstract 8590.
19. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538-48.
20. Bender LM, Cotten SW, Fedoriw Y, Willis MS, McCudden CR. Evaluation of digital images for identification and characterization of monoclonal immunoglobulins by immunofixation. Clin Biochem 2013;46:255-8.
21. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
22. Durie BG, Miguel JF, Blade J, Rajkumar SV. Clarification of the definition of complete response in multiple myeloma. Leukemia 2015;29:2416-7.